Our studies have indicated that dietary Dunaliella bardawil supplementation may inhibit the development of obesity-associated pathological disorders, such as dyslipidemia, adipose tissue inflammation, diabetes, atherosclerosis, and fatty liver in Ldlr−/−, Apoe−/−, and db/db mice models [14,17,18,19]. This evidence concerns the gene LDLR and atherosclerosis.